We report these cases to show that inhibition of interferon pathway through IFNγ inhibition and long term suppression with JAK inhibitors have potential therapeutic benefits in those with HLH and trisomy 21, as well as other disorders driven by interferon, which could lead to more targeted and earlier therapies. Here, IFNG is linked to trisomy 21.